Integra Lifesciences Holdings Free Cash Flow (FCF) History (IART)
Integra Lifesciences Holdings reported −$31.1M in free cash flow for fiscal 2025, a decrease of $56.0M from the previous fiscal year, with a free cash flow margin of −1.90%.
View full Integra Lifesciences Holdings company overviewIntegra Lifesciences Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$31.1M | −$56.0M | — | −1.90% |
| 2024 | 2024-12-31 | $25.0M | −$48.1M | −65.84% | +1.55% |
| 2023 | 2023-12-31 | $73.1M | −$149.0M | −67.10% | +4.74% |
| 2022 | 2022-12-31 | $222.1M | −$42.3M | −15.99% | +14.26% |
| 2021 | 2021-12-31 | $264.4M | $99.5M | +60.30% | +17.14% |
| 2020 | 2020-12-31 | $164.9M | $3.0M | +1.88% | +12.02% |
| 2019 | 2019-12-31 | $161.9M | $40.0M | +32.76% | +10.67% |
| 2018 | 2018-12-31 | $121.9M | $50.9M | +71.65% | +8.28% |
| 2017 | 2017-12-31 | $71.0M | $2.0M | +2.84% | +5.98% |
| 2016 | 2016-12-31 | $69.1M | −$2.4M | −3.31% | +6.96% |
| 2015 | 2015-12-31 | $71.4M | $26.2M | +57.97% | — |
| 2014 | 2014-12-31 | $45.2M | $34.3M | +312.37% | — |
| 2013 | 2013-12-31 | $11.0M | $20.9M | — | — |
| 2012 | 2012-12-31 | −$9.9M | −$75.8M | — | — |
| 2011 | 2011-12-31 | $65.9M | −$2.5M | −3.70% | — |
| 2010 | 2010-12-31 | $68.4M | −$49.6M | −42.00% | — |
| 2009 | 2009-12-31 | $118.0M | $58.8M | +99.36% | — |
| 2008 | 2008-12-31 | $59.2M | — | — | — |
Integra Lifesciences Holdings quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.5M | $21.7M | — | +2.51% |
| Q1 2026 | 2026-03-31 | −$5.0M | $35.1M | — | −1.29% |
| Q4 2025 | 2025-12-31 | −$5.4M | −$26.5M | — | −1.24% |
| Q3 2025 | 2025-09-30 | $25.8M | $32.9M | — | +6.40% |
| Q2 2025 | 2025-06-30 | −$11.2M | −$21.9M | — | −2.70% |
| Q1 2025 | 2025-03-31 | −$40.2M | −$40.5M | — | −10.50% |
| Q4 2024 | 2024-12-31 | $21.1M | −$13.1M | −38.21% | +4.78% |
| Q3 2024 | 2024-09-30 | −$7.2M | −$20.9M | — | −1.88% |
| Q2 2024 | 2024-06-30 | $10.7M | −$2.0M | −16.00% | +2.56% |
| Q1 2024 | 2024-03-31 | $291,000 | −$12.2M | −97.66% | +0.08% |
| Q4 2023 | 2023-12-31 | $34.2M | −$36.7M | −51.73% | +8.62% |
| Q3 2023 | 2023-09-30 | $13.7M | −$45.5M | −76.86% | +3.58% |
| Q2 2023 | 2023-06-30 | $12.7M | −$44.3M | −77.69% | +3.34% |
| Q1 2023 | 2023-03-31 | $12.5M | −$22.6M | −64.44% | +3.27% |
| Q4 2022 | 2022-12-31 | $70.9M | $29.0M | +69.36% | +17.81% |
| Q3 2022 | 2022-09-30 | $59.2M | −$16.3M | −21.64% | +15.36% |
| Q2 2022 | 2022-06-30 | $57.1M | −$27.6M | −32.58% | +14.35% |
| Q1 2022 | 2022-03-31 | $35.0M | −$27.4M | −43.89% | +9.30% |
| Q4 2021 | 2021-12-31 | $41.9M | −$30.0M | −41.74% | +10.32% |
| Q3 2021 | 2021-09-30 | $75.5M | $12.6M | +20.00% | +19.51% |
| Q2 2021 | 2021-06-30 | $84.7M | $58.8M | +226.86% | +21.71% |
| Q1 2021 | 2021-03-31 | $62.4M | $58.1M | +1352.99% | +17.33% |
| Q4 2020 | 2020-12-31 | $71.8M | $4.8M | +7.23% | +18.48% |
| Q3 2020 | 2020-09-30 | $62.9M | $12.3M | +24.21% | +16.99% |
| Q2 2020 | 2020-06-30 | $25.9M | −$5.0M | −16.07% | +10.01% |
| Q1 2020 | 2020-03-31 | $4.3M | −$9.1M | −67.94% | +1.21% |
| Q4 2019 | 2019-12-31 | $67.0M | $50.0M | +293.99% | +16.95% |
| Q3 2019 | 2019-09-30 | $50.6M | −$11.9M | −19.07% | +13.36% |
| Q2 2019 | 2019-06-30 | $30.9M | $14.6M | +90.34% | +8.04% |
| Q1 2019 | 2019-03-31 | $13.4M | −$12.7M | −48.75% | +3.72% |
| Q4 2018 | 2018-12-31 | $17.0M | $19.2M | — | +4.44% |
| Q3 2018 | 2018-09-30 | $62.6M | $25.1M | +67.13% | +17.11% |
| Q2 2018 | 2018-06-30 | $16.2M | $161,000 | +1.00% | +4.43% |
| Q1 2018 | 2018-03-31 | $26.1M | $6.5M | +32.77% | +7.32% |
| Q4 2017 | 2017-12-31 | −$2.1M | $12.5M | — | −0.58% |
| Q3 2017 | 2017-09-30 | $37.4M | −$2.3M | −5.90% | +13.43% |
| Q2 2017 | 2017-06-30 | $16.1M | −$13.8M | −46.16% | +5.69% |
| Q1 2017 | 2017-03-31 | $19.7M | $5.6M | +39.31% | +7.61% |
| Q4 2016 | 2016-12-31 | −$14.7M | −$27.2M | — | −5.74% |
| Q3 2016 | 2016-09-30 | $39.8M | $25.5M | +179.25% | +15.90% |
| Q2 2016 | 2016-06-30 | $29.8M | $11.5M | +62.37% | +11.96% |
| Q1 2016 | 2016-03-31 | $14.1M | −$12.2M | −46.23% | +5.97% |
| Q4 2015 | 2015-12-31 | $12.5M | −$1.1M | −7.97% | — |
| Q3 2015 | 2015-09-30 | $14.3M | −$10.4M | −42.21% | +6.30% |
| Q2 2015 | 2015-06-30 | $18.4M | $11.3M | +161.52% | +8.63% |
| Q1 2015 | 2015-03-31 | $26.3M | $26.4M | — | +12.98% |
| Q4 2014 | 2014-12-31 | $13.6M | $6.5M | +91.47% | — |
| Q3 2014 | 2014-09-30 | $24.7M | $7.1M | +40.41% | +12.48% |
| Q2 2014 | 2014-06-30 | $7.0M | $17.7M | — | +3.03% |
| Q1 2014 | 2014-03-31 | −$81,000 | $2.9M | — | −0.04% |
| Q4 2013 | 2013-12-31 | $7.1M | $35.2M | — | — |
| Q3 2013 | 2013-09-30 | $17.6M | $9.4M | +114.37% | +8.24% |
| Q2 2013 | 2013-06-30 | −$10.7M | $1.3M | — | −5.21% |
| Q1 2013 | 2013-03-31 | −$3.0M | −$24.9M | — | −1.53% |
| Q4 2012 | 2012-12-31 | −$28.1M | −$49.7M | — | — |
| Q3 2012 | 2012-09-30 | $8.2M | −$3.4M | −29.09% | +3.90% |
| Q2 2012 | 2012-06-30 | −$12.0M | −$29.3M | — | — |
| Q1 2012 | 2012-03-31 | $21.9M | $6.6M | +42.87% | — |
| Q4 2011 | 2011-12-31 | $21.7M | $11.5M | +112.49% | — |
| Q3 2011 | 2011-09-30 | $11.6M | −$10.9M | −48.52% | — |
| Q2 2011 | 2011-06-30 | $17.4M | $15.6M | +907.95% | — |
| Q1 2011 | 2011-03-31 | $15.3M | −$6.9M | −30.91% | — |
| Q4 2010 | 2010-12-31 | $10.2M | −$12.5M | −55.08% | — |
| Q3 2010 | 2010-09-30 | $22.4M | — | — | — |
| Q2 2010 | 2010-06-30 | $1.7M | — | — | — |
| Q1 2010 | 2010-03-31 | $22.2M | — | — | — |
| Q3 2009 | 2009-09-30 | $22.7M | — | — | — |
Integra Lifesciences Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $164.9M to −$31.1M, a net decrease of $196.0M. Integra Lifesciences Holdings's latest reported quarter, Q2 2026, generated $10.5M in free cash flow, an increase of $21.7M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Integra Lifesciences Holdings filings at SEC.gov ↗